TNDM Stock Chart & Stats
$745.00
$0.00(0.00%)
At close: 4:00 PM EDT
$745.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$745.00 - $745.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$25.55B
Enterprise Value$1.32B
Total Cash (Recent Filing)$456.00M
Total Debt (Recent Filing)$739.25M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Nov 05, 2026EPS Estimate
-4.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding69,578,705
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$496.69Price Target Upside-33.33% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-12.57
Revenue Forecast (FY)$20.08B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueTandem combines one-time pump sales with recurring consumable demand because users need disposable supplies for daily insulin delivery. This installed-base model can support repeat revenue, deepen customer relationships, and improve revenue durability as the pump population expands.
Improving Growth And MarginsRecord quarterly sales and shipments, together with gross-margin expansion and four consecutive quarters of positive adjusted EBITDA margin, indicate meaningful operating progress. If sustained, this combination can improve earnings quality and increase the company's capacity to fund growth internally.
Product And International ExpansionExpanding Mobi availability across 12 additional countries broadens Tandem's commercial reach and supports international adoption of its automated insulin delivery ecosystem. Wider distribution can diversify revenue sources and create longer-term opportunities for related pump supplies.
Bears Say
High Financial LeverageThe thin equity cushion relative to debt increases financial risk while Tandem's earnings remain negative. High leverage can reduce flexibility to invest, absorb operating setbacks, or respond to competitive changes, making sustained execution more important over the coming quarters.
Cash Generation Not Yet DurableAlthough operating cash flow has improved from the prior year, it remains small relative to losses and does not cover investment needs, leaving free cash flow negative. Continued cash consumption could constrain strategic investment and increase reliance on existing liquidity or financing.
Tubeless Competition And Execution RiskNew tubeless competitors could intensify pressure in a high-growth segment where Tandem is relying on Mobi to compete effectively. The need for regulatory clearance and successful launch execution creates a risk that product timing or market adoption may not meet expectations.
Tandem Diabetes Care News
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $745.00 and its highest was $745.00 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $25.55B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Nov 05, 2026 which is in 7 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Aug 06, 2026. The company reported -$5.729 earnings per share for the quarter, beating the consensus estimate of -$5.991 by $0.261.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Overvalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -4.57.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 69,578,705 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$5.729 in its last earnings report, beating expectations of -$5.991. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in MX:TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$496.69 (-33.33% Downside)
$496.69 (-33.33% Downside)
Blogger Sentiment
Neutral
MX:TNDM Sentiment 50%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.33%
12-Months-Change
Fundamentals
Return on Equity
-45.97%
Trailing 12-Months
Asset Growth
31.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TNDM Company Deck
TNDM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and financial progress: record quarterly sales and shipments, strong international growth, notable gross margin expansion, improving profitability, and clear product and pipeline milestones (Mobi tubeless filing, AdaNet IDE). Near-term challenges include infusion set supplier constraints, a temporary revenue headwind and margin variability from the pharmacy PayGo transition, distributor destocking, and the need to accelerate U.S. new-starts in H2 to meet guidance. On balance, the positives — sizable revenue and margin improvements, product launches, and early PayGo traction — outweigh the near-term operational headwinds, with the company reiterating full-year guidance.View all MX:TNDM earnings summariesTNDM Revenue Breakdown
74.21% U.S.
25.79% International
TNDM Stock 12 Month Forecast
Average Price Target
$496.69
▼(-33.33% Downside)